Loading the comparison…
Loading the comparison…
Any covered state and procedure, side by side
| Incontinence, prolapse & sacral neuromodulation · New Jersey | Incontinence, prolapse & sacral neuromodulation · New York | |
|---|---|---|
| Surgeons, 2024 | 26 | 38 |
| Medicare fee-for-service cases | 1,784 | 3,138 |
| Growth since 2019 (Medicare FFS) | −4.1%/yr | −0.8%/yr |
| Forecast cases (Medicare FFS) | 1,880 in 2030 | 3,860 in 2030 |
| Forecast growth | +0.9%/yr to 2030 | +3.5%/yr to 2030 |
| Per 1,000 Medicare beneficiaries | 1.7 | 1.7 |
| Medicare Advantage share | 45% | 57% |
| Out of hospital | 9% (+3 pts since 2019) | 8% (+5 pts since 2019) |
| Cases per surgeon | 69 | 83 |
| Top 10 surgeons' share | 65% | 48% |
| Surgeons growing | 5 | 7 |
| New since the base year | 5 | 3 |
| Likely to stop billing it | 4 by 2026 | 7 by 2026 |
| Forecast miss, 1 year (procedure) | 6% | 6% |
| Company payments per surgeon | $6,154 | $19K |
The counts above are the surgeons MedaRep names: who is growing, who is new, who is likely to stop and which companies engage them.